局部麻醉经会阴穿刺活检与经直肠前列腺穿刺活检在前列腺癌检出中的比较(TRANSLATE):一项多中心、随机、对照试验
TRANSLATE多中心随机对照试验比较局部麻醉超声引导经会阴穿刺活检(LATP)与经直肠超声引导穿刺活检(TRUS)在前列腺癌检出、副作用及耐受性方面的差异。结果显示LATP组检出具Gleason分级分组(GGG)2级或以上前列腺癌的比例高于TRUS组(60% vs 54%,OR 1.32,95%CI 1.03-1.70,p=0.031),LATP组因感染住院的比例低于TRUS组,但LATP组即刻疼痛和尴尬的报告率更高。
要点
- LATP组GGG≥2级前列腺癌检出率为60%(329/547),TRUS组为54%(294/540),OR 1.32(95%CI 1.03-1.70),p=0.031。
- LATP组因感染住院2例(<1%,2/562),TRUS组9例(2%,9/564)。
- LATP组报告即刻疼痛和尴尬的比例为38%(216/562),TRUS组为27%(153/564),OR 1.84(95%CI 1.40-2.43)。
核心结论
- 在因疑似前列腺癌接受检查的未穿刺人群中,LATP活检较TRUS检出更多GGG 2级或以上病变。
- 这些发现有助于患者、临床医生、临床指南和政策制定者了解LATP与TRUS前列腺穿刺活检之间的重要权衡。
研究设计与样本
- TRANSLATE是一项在英国十家医院进行的多中心、随机、对照试验。
- 纳入年龄18岁及以上、因年龄特异性前列腺特异性抗原升高或直肠指检异常而怀疑前列腺癌、且未穿刺并已接受1.5特斯拉或更高场强MRI扫描的个体。
- 排除既往前列腺穿刺、广泛局部病变易于通过任何穿刺检出(前列腺特异性抗原>50 ng/mL或MRI显示整个腺体被肿瘤替代)、并发或近期尿路感染症状、免疫抑制病史、需要增强抗生素预防、直肠缺如或无法摆截石位的个体。
- 参与者按1:1比例随机分配接受LATP或TRUS活检,使用基于网络的软件和最小化算法确保活检组间在招募中心和MRI病灶位置等因素上均衡分配。
- 主要结局为GGG 2级或以上前列腺癌的检出,在改良意向治疗人群(所有随机分配且有活检结果的参与者)中分析。
主要发现
- 2021年12月3日至2023年9月26日,2727名评估个体中2078名(76%)符合条件,1126名(41%)同意参与;1126名参与者中1044名(93%)为英国白人。
- 参与者被分配至TRUS组(n=564)或LATP组(n=562),在活检时、活检后7天、35天和4个月随访。
- LATP组547名有活检结果的参与者中329名(60%)检出GGG 2级或以上前列腺癌,TRUS组540名中294名(54%)检出(OR 1.32,95%CI 1.03-1.70;p=0.031)。
- 活检后35天内因感染住院:LATP组562名中2名(<1%),TRUS组564名中9名(2%)。
- 活检相关总体并发症报告:LATP组454/562(81%),TRUS组436/564(77%),OR 1.23(95%CI 0.93-1.65),无统计学显著差异。
关键数值与推荐
- 主要结局:LATP组GGG 2级或以上前列腺癌检出329/547(60%),TRUS组294/540(54%),OR 1.32(95%CI 1.03-1.70),p=0.031。
- 因感染住院(活检后35天内):LATP组2/562(<1%),TRUS组9/564(2%)。
- 总体活检相关并发症:LATP组454/562(81%),TRUS组436/564(77%),OR 1.23(95%CI 0.93-1.65),无统计学显著差异。
- 需导尿的尿潴留:LATP组35/562(6%),TRUS组27/564(5%)。
- 国际前列腺症状评分中位数:LATP组8(IQR 4-14),TRUS组8(IQR 4-13),OR 0.36(95%CI -0.38至1.10),无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
- 作者指出这些发现将有助于患者、临床医生、临床指南和政策制定者了解LATP与TRUS前列腺穿刺活检之间的重要权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer diagnosis requires biopsy, traditionally performed under local anaesthetic with ultrasound guidance via a transrectal approach (TRUS). Local anaesthetic ultrasound-guided transperineal biopsy (LATP) is gaining popularity in this setting; however, there is uncertainty regarding prostate sampling, infection rates, tolerability, side-effects, and cost-effectiveness. TRANSLATE was a randomised clinical trial that aimed to compare detection of Gleason Grade Group (GGG) 2 or higher prostate cancer, side-effects, tolerability, and patient-reported outcomes, after LATP versus TRUS biopsy. METHODS: In this randomised clinical trial which was done at ten hospitals in the UK, patients aged 18 years or older were eligible if investigated for suspected prostate cancer based on elevated age-specific prostate-specific antigen or abnormal digital rectal examination, and if biopsy-naive having received pre-biopsy MRI on a 1·5 or higher Tesla scanner. Individuals were excluded if they had any previous prostate biopsy, extensive local disease easily detectable by any biopsy (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, history of immunocompromise, need for enhanced antibiotic prophylaxis, absent rectum, or inability to position in lithotomy. Participants were randomly assigned in a 1:1 ratio to receive LATP or TRUS biopsy, using web-based software with a randomisation sequence using a minimisation algorithm to ensure balanced allocation across biopsy groups for minimisation factors (recruitment site, and location of the MRI lesion). The primary outcome was detection of GGG 2 or higher prostate cancer, analysed in the modified intention-to-treat population (all randomly assigned to treatment who had a biopsy result available). Key secondary endpoints assessing post-biopsy adverse events were infection, bleeding, urinary and sexual function, tolerability, and patient-reported outcomes. This trial is registered with ClinicalTrials.gov (NCT05179694) and at ISRCTN (ISRCTN98159689), and is complete. FINDINGS: Between Dec 3, 2021, and Sept 26, 2023, 2078 (76%) of 2727 assessed individuals were eligible, and 1126 (41%) of 2727 agreed to participate. 1044 (93%) of the 1126 participants were White British. Participants were allocated to TRUS (n=564) or LATP (n=562) biopsy, and were followed up at time of biopsy, and at 7 days, 35 days, and 4 months post-biopsy. We found GGG 2 or higher prostate cancer in 329 (60%) of 547 participants with biopsy results randomly assigned to LATP compared with 294 (54%) of 540 participants with biopsy results randomly assigned to TRUS biopsy (odds ratio [OR] 1·32 [95% CI 1·03-1·70]; p=0·031). Infection requiring admission to hospital within 35 days post-biopsy occurred in 2 (<1%) of 562 participants in the LATP group compared with 9 (2%) of 564 in the TRUS group. No statistically significant difference was observed in the reporting of overall biopsy-related complications (LATP 454 [81%] of 562 vs TRUS 436 [77%] of 564, OR 1·23 [95% CI 0·93 to 1·65]), urinary retention requiring catheterisation (LATP 35 [6%] of 562 vs TRUS 27 [5%] of 564), urinary symptoms (median International Prostate Symptom Score: LATP 8 [IQR 4-14] vs TRUS 8 [4-13], OR 0·36 [95% CI -0·38 to 1·10]), nor sexual function (median International Index of Erectile Function score: LATP 5 [2-25] vs TRUS 8 [3-24], OR -0·60 [-1·79 to 0·58]) at 4 months after biopsy. Trial participants more commonly reported LATP biopsy to be immediately painful and embarrassing compared with TRUS (LATP 216 [38%] of 562 vs TRUS 153 [27%] of 564; OR 1·84 [95% CI 1·40 to 2·43]). Serious adverse events occurred in 14 (2%) of 562 participants in the LATP group and 25 (4%) of 564 in the TRUS group. INTERPRETATION: Among biopsy-naive individuals being investigated for possible prostate cancer, biopsy with LATP led to greater detection of GGG 2 or higher disease compared with TRUS. These findings will help to inform patients, clinicians, clinical guidelines, and policy makers regarding the important trade-offs between LATP and TRUS prostate biopsy. FUNDING: National Institute for Health and Care Research (NIHR) Health Technology Assessment.
引用
- Bryant RJ, Marian IR, Williams R, et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol. 2025. PMID: 40139210. doi:10.1016/S1470-2045(25)00100-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。